Get the Stockscreener App
5.8988
23.69%
1.1288
I Mab Adr stock is traded at $5.8988, with a volume of 4.08M.
It is up +23.69% in the last 24 hours and up +44.25% over the past month.
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$4.77
Open:
$4.87
24h Volume:
4.08M
Relative Volume:
1.72
Market Cap:
$677.45M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
-2.3762
EPS:
-2.4825
Net Cash Flow:
$-167.78M
1W Performance:
+35.63%
1M Performance:
+44.25%
6M Performance:
+781.65%
1Y Performance:
+364.57%
1-Day Range:
$4.7559
$6.16
1-Week Range:
$4.19
$6.16
52-Week Range:
$0.595
$6.16
I Mab Adr Stock (IMAB) Company Profile
Compare IMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
5.8912 | 549.82M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.99 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.71 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Initiated | Leerink Partners | Outperform |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Dec-09-21 | Initiated | Siebert Williams Shank | Buy |
| Jun-02-21 | Initiated | Daiwa Securities | Buy |
| Mar-15-21 | Initiated | Needham | Buy |
| Mar-03-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-25-21 | Initiated | Piper Sandler | Overweight |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-20 | Initiated | China Renaissance | Buy |
| Feb-11-20 | Initiated | Jefferies | Buy |
View All
I Mab Adr Stock (IMAB) Latest News
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know - sharewise.com
What Makes IMab (IMAB) a New Buy Stock - sharewise.com
I-Mab Sponsored ADR (NASDAQ:IMAB) Given Average Rating of "Buy" by Analysts - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
I-Mab at H.C. Wainwright Conference: Strategic U.S. Shift and Jeva Stomach Focus - Investing.com
I-Mab (NASDAQ:IMAB) Now Covered by BTIG Research - Defense World
I-Mab stock initiated with Buy rating at BTIG on gastric cancer drug potential - Investing.com
I-Mab (NASDAQ:IMAB) Receives Buy Rating from Needham & Company LLC - Defense World
I-Mab to initiate phase 2 study for gastric cancer drug in Q1 2026 - Investing.com
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce… - inkl
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Equities Analysts Offer Predictions for I-Mab Q3 Earnings - MarketBeat
I-Mab stock price target raised to $8 from $6 at Brookline Capital - Investing.com
Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice - Yahoo Finance
I-Mab (NASDAQ:IMAB) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
HC Wainwright Comments on I-Mab’s Q3 Earnings (NASDAQ:IMAB) - Defense World
I-Mab (NASDAQ:IMAB) Rating Increased to Buy at Wall Street Zen - Defense World
I-Mab’s Q2 2025: Clinical Progress and Financial Strength - MSN
H.C. Wainwright reiterates Buy rating on I-Mab stock, citing strong trial data - Investing.com
I-Mab ADR (IMAB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
I-Mab Reports Strong Financials and Clinical Progress in August 2025 - TipRanks
I-Mab (IMAB) Expected to Announce Earnings on Wednesday - Defense World
UnitedHealth, Cisco Lead Market Cap Stock Movers on Friday - Investing.com
Kimball Electronics Posts Better-Than-Expected… - inkl
Kimball Electronics Posts Better-Than-Expected Earnings, Joins Terawulf, Dlocal, Equinox Gold And Other Big Stocks Moving Higher On Thursday - Benzinga
The Psychology of I-Mab ADR Inc. (IMAB) Price Performance: Understanding Market Sentiment - investchronicle.com
I-Mab (NASDAQ:IMAB) Trading 14.1% Higher – Here’s Why - Defense World
I-Mab completes enrollment for givastomig trial ahead of schedule By Investing.com - Investing.com South Africa
I-Mab completes enrollment for givastomig trial ahead of schedule - Investing.com
Adverse Reactions to Tremelimumab, Durvalumab in Liver Cancer - BIOENGINEER.ORG
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System. - Physician's Weekly
I-Mab ADR: Analyzing IMAB Stock Trends - investchronicle.com
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares - GlobeNewswire Inc.
I-Mab ADR (IMAB) Stock: Navigating a Year of Stock Volatility - investchronicle.com
I-Mab acquires Bridge Health to strengthen givastomig development By Investing.com - Investing.com South Africa
I-Mab acquires Bridge Health to strengthen givastomig development - Investing.com India
Best Income Stocks to Buy for July 16th - The Globe and Mail
I-MAB files 6-K to amend US$21M ADS shelf registration | BQ SEC FilingForm 6-K - Stock Titan
I-Mab reports 83% response rate for givastomig in gastric cancer study - Investing.com India
I-Mab’s givastomig shows promising results in gastric cancer study - Investing.com
I-Mab stock maintains buy rating at H.C. Wainwright on strong cancer data - Investing.com
I-Mab reports 71% response rate for gastric cancer drug in trial - Investing.com
H.C. Wainwright reiterates buy rating on I-Mab stock ahead of key data By Investing.com - Investing.com South Africa
I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations - Investing.com
I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations By Investing.com - Investing.com South Africa
Market Momentum: Abpro Holdings Inc (ABP) Registers a 3.72 Increase, Closing at 0.22 - DWinneX
Unity Software Inc’s Market Journey: Closing Strong at 24.40, Up 3.13 - DWinneX
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross - MSN
I-Mab regains Nasdaq compliance as shares maintain $1 minimum bid - Investing.com India
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance
Figure 1. Protein and mRNA expressions of P-glycoprotein in BEL-7402... - researchgate.net
I Mab Adr Stock (IMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):